Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Dan Vinh Nguyen, Angela Linderholm, Angela Franciska Haczku, Nicholas Kenyon

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Alterations in arginine metabolism and accelerated formation of advanced glycation end-products (AGEs), crucial mechanisms in obesity-related asthma, can be modulated by glucagon-like peptide 1 (GLP-1).l-arginine dysregulation in obesity promotes inflammation and bronchoconstriction. Prolonged hyperglycemia, dyslipidemia, and oxidative stress leads to production of AGEs, that bind to their receptor (RAGE) further potentiating inflammation. By binding to its widely distributed receptor, GLP-1 blunts the effects of RAGE activation and arginine dysregulation. The GLP-1 pathway, while comprehensively studied in the endocrine and cardiovascular literature, is under-recognized in pulmonary research. Insights into GLP-1 and the lung may lead to novel treatments for obesity-related asthma.

Original languageEnglish (US)
JournalPharmacology and Therapeutics
StateAccepted/In press - 2017


  • Advanced glycation end products
  • Arginine
  • Asthma
  • Glucagon-like peptide 1
  • Obesity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma'. Together they form a unique fingerprint.

Cite this